India’s NPPA Rejects Pharma Requests To Increase Insulin Prices
This article was originally published in PharmAsia News
Executive Summary
India’s National Pharmaceutical Pricing Authority has rejected a request from local and foreign drug makers Biocon, Cadila, Eli Lilly and Lupin to be allowed to increase the prices of their insulins.